Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Mar. 31, 2019 | May 13, 2019 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q3 | |
Trading Symbol | SSY | |
Entity Registrant Name | SUNLINK HEALTH SYSTEMS INC | |
Entity Central Index Key | 0000096793 | |
Current Fiscal Year End Date | --06-30 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Common Stock, Shares Outstanding | 6,986,855 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2019 | Jun. 30, 2018 |
Current Assets: | ||
Cash and cash equivalents | $ 9,160 | $ 3,456 |
Receivables - net | 5,251 | 4,823 |
Inventory | 2,003 | 1,854 |
Current assets held for sale | 0 | 40 |
Prepaid expense and other assets | 2,664 | 2,937 |
Total current assets | 19,078 | 13,110 |
Property, plant and equipment, at cost | 20,154 | 19,867 |
Less accumulated depreciation | 14,666 | 13,971 |
Property, plant and equipment - net | 5,488 | 5,896 |
Noncurrent Assets: | ||
Intangible assets - net | 1,383 | 1,470 |
Income tax receivable | 305 | 305 |
Noncurrent assets held for sale | 0 | 4,510 |
Other noncurrent assets | 806 | 885 |
Total noncurrent assets | 2,494 | 7,170 |
TOTAL ASSETS | 27,060 | 26,176 |
Current liabilities: | ||
Accounts payable | 1,527 | 1,239 |
Current maturities of long-term debt, net of debt issuance costs | 319 | 255 |
Accrued payroll and related taxes | 2,148 | 1,959 |
Due to third party payors | 275 | 290 |
Other accrued expenses | 1,771 | 1,108 |
Total current liabilities | 6,040 | 4,851 |
Long-Term Liabilities | ||
Long-term debt, net of debt issuance costs | 2,739 | 2,803 |
Noncurrent liability for professional liability risks | 774 | 996 |
Other noncurrent liabilities | 236 | 340 |
Total long-term liabilities | 3,749 | 4,139 |
Commitment and Contingencies | ||
Shareholders’ Equity | ||
Preferred Shares, authorized and unissued, 2,000 shares | 0 | 0 |
Issued and outstanding, 6,987 shares at March 31, 2019 and 7,347 shares at June 30, 2018 | 3,493 | 3,673 |
Additional paid-in capital | 10,745 | 10,947 |
Retained earnings | 3,210 | 2,743 |
Accumulated other comprehensive loss | (177) | (177) |
Total Shareholders’ Equity | 17,271 | 17,186 |
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ 27,060 | $ 26,176 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2019 | Jun. 30, 2018 |
Statement Of Financial Position [Abstract] | ||
Preferred shares, authorized | 2,000,000 | 2,000,000 |
Preferred shares, unissued | 2,000,000 | 2,000,000 |
Common shares, without par value | ||
Common shares, issued | 6,987,000 | 7,347,000 |
Common shares, outstanding | 6,987,000 | 7,347,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | |
Net revenues | $ 12,361 | $ 11,333 | $ 34,719 | $ 34,990 |
Costs and Expenses | ||||
Cost of goods sold | 14,623 | |||
Salaries, wages and benefits | 4,931 | 4,806 | 14,225 | 14,068 |
Supplies | 329 | 327 | 942 | 958 |
Other operating expenses | 865 | 778 | 2,858 | 2,702 |
Rent and lease expense | 155 | 154 | 458 | 463 |
EHR incentive payments | 0 | 0 | 0 | (21) |
Depreciation and amortization | 367 | 383 | 1,056 | 1,096 |
Operating Loss | (488) | (720) | (1,348) | (498) |
Other Income (Expense): | ||||
Gains on sale of assets | 0 | 183 | 454 | 181 |
Gain on economic damages claim, net | 0 | 0 | 0 | 944 |
Loss on extinguishment of debt | 0 | 0 | 0 | (238) |
Interest expense, net | (63) | (56) | (185) | (302) |
Earnings (Loss) from Continuing Operations before income taxes | (551) | (593) | (1,079) | 87 |
Income Tax Benefit | (226) | 0 | (226) | (296) |
Earnings (Loss) from Continuing Operations | (325) | (593) | (853) | 383 |
Earnings (Loss) from Discontinued Operations, net of tax | 1,367 | 5 | 1,320 | (522) |
Net Earnings (Loss) | 1,042 | (588) | 467 | (139) |
Other comprehensive income | 0 | 0 | 0 | 0 |
Comprehensive Earnings (Loss) | $ 1,042 | $ (588) | $ 467 | $ (139) |
Continuing Operations: | ||||
Basic | $ (0.05) | $ (0.08) | $ (0.12) | $ 0.04 |
Diluted | (0.05) | (0.08) | (0.12) | 0.04 |
Discontinued Operations: | ||||
Basic | 0.20 | 0 | 0.18 | (0.06) |
Diluted | 0.20 | 0 | 0.18 | (0.06) |
Net Earnings (Loss): | ||||
Basic | 0.15 | (0.08) | 0.06 | (0.02) |
Diluted | $ 0.15 | $ (0.08) | $ 0.06 | $ (0.02) |
Weighted-Average Common Shares Outstanding: | ||||
Basic | 6,987 | 7,417 | 7,203 | 8,564 |
Diluted | 6,987 | 7,417 | 7,203 | 8,632 |
Product [Member] | ||||
Costs and Expenses | ||||
Cost of goods sold | $ 5,539 | $ 5,073 | $ 14,711 | $ 14,623 |
Service [Member] | ||||
Costs and Expenses | ||||
Cost of goods sold | $ 663 | $ 532 | $ 1,817 | $ 1,599 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Statement Of Cash Flows [Abstract] | ||
Net Cash Used in Operating Activities | $ (517) | $ (33) |
Cash Flows Provided by (Used in) Investing Activities: | ||
Expenditures for property, plant and equipment - continuing operations | (867) | (813) |
Expenditures for property, plant and equipment - discontinued operations | (172) | (689) |
Proceeds from sale of Parkside | 6,899 | 0 |
Proceeds from sale of other assets | 937 | 412 |
Net Cash Provided by (Used) in Investing Activities | 6,797 | (1,090) |
Cash Flows Provided by (Used in) Financing Activities: | ||
Payments on long-term debt | (193) | (3,856) |
Repurchase of common shares | (383) | (2,974) |
Restricted cash deposit released | 0 | 1,000 |
Net Cash Used in Financing Activities | (576) | (5,830) |
Net Increase (Decrease) in Cash and Cash Equivalents | 5,704 | (6,953) |
Cash and Cash Equivalents Beginning of Period | 3,456 | 10,494 |
Cash and Cash Equivalents End of Period | 9,160 | 3,541 |
Cash Paid for: | ||
Interest | 168 | 269 |
Income taxes | 0 | 0 |
Non-cash investing and financing activities: | ||
Assets acquired under capital lease obligations | $ 176 | $ 0 |
Basis of Presentation and Adopt
Basis of Presentation and Adoption of Recently Issued Accounting Standards | 9 Months Ended |
Mar. 31, 2019 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Basis of Presentation and Adoption of Recently Issued Accounting Standards | Note 1. –Basis of Presentation and Adoption of Recently Issued Accounting Standards Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2019 and for the three and nine month periods ended March 31, 2019 and 2018 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2018 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2018, filed with the SEC on September 25, 2018. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2019 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. Adoption of Recently Issued Accounting Standards ASC 606, “Revenue from Contracts with Customers” Effective July 1, 2018, the Company adopted the provisions of Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” (“ASC 606”), which supersedes most existing revenue recognition guidance, including industry-specific healthcare guidance, by applying the full retrospective method for all periods presented. ASC 606 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The adoption of the provisions of ASC 606 had no material impact on the Company’s current or historical financial position, results of operations or cash flows. Additionally, management does not anticipate that the provisions of ASC 606 will have a material impact on the amount or timing of when the Company recognizes revenue prospectively. However, in accordance with ASC 606, the Company now recognizes the majority of its previously reported provision for doubtful accounts, primarily related to its self-pay patient population, as a direct reduction to revenues as an implicit pricing concession, instead of separately as a discrete deduction to arrive at revenue, and the related presentation of the allowance for doubtful accounts has been eliminated for all periods presented. The Company’s revenue recognition and accounts receivable policies are more fully described in Note 5. |
Business Operations
Business Operations | 9 Months Ended |
Mar. 31, 2019 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Business Operations | Note 2. – Business Operations Business Operations SunLink Health Systems, Inc., through subsidiaries, owns businesses that provide healthcare products and services in certain markets in the southeastern United States. Unless the context indicates otherwise, all references to “SunLink,” “we,” “our,” “ours,” “us” and the “Company” refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to “we,” “our,” “ours,” and “us” in such context refer to the operations of our subsidiaries. Our business is composed of two business segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an 84- bed community hospital and a 66- bed nursing home in Mississippi, an IT service company based in Georgia, and healthcare facilities, which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines. The business strategy of SunLink is to focus its efforts on improving the operations, services and profitability of its existing Healthcare Services and Pharmacy businesses while seeking to sell certain of its underperforming subsidiaries’ assets. On March 17, 2019, a subsidiary of the Company completed the sale of a nursing home and related real estate for $7,300 subject to adjustment for the book value of certain assets and liabilities on the sale date. The pre-tax gain on the sale was $2,136, which is also subject to adjustment for the book value of certain assets and liabilities on the sale date. Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares, including in tender offers completed in February and December 2017, and open market repurchases of its common shares in December 2018, and to make improvements to its Healthcare Services businesses. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to, among other things, prepay debts, return capital to shareholders including through potential public or private purchases of shares, improve its existing businesses, make selective acquisitions of Healthcare Services and Pharmacy businesses and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis. The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its Pharmacy business lines. The Company has repurchased 359,959 common shares pursuant to a stock repurchase program announced on November 29, 2018, which authorizes the repurchase of a total of 750,000 common shares. |
Discontinued Operations
Discontinued Operations | 9 Months Ended |
Mar. 31, 2019 | |
Discontinued Operations And Disposal Groups [Abstract] | |
Discontinued Operations | Note 3. – Discontinued Operations All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation. Results for all of the businesses included in discontinued operations are presented in the following table: Three Months Ended Nine Months Ended March 31, March 31, 2019 2018 2019 2018 Net Revenues: Parkside $ 1,723 $ 1,846 $ 5,640 $ 5,223 Sold Hospitals 3 77 15 71 $ 1,726 $ 1,923 $ 5,655 $ 5,294 Loss before income taxes: Parkside $ (185 ) $ (10 ) $ (121 ) $ (411 ) Sold Hospitals (126 ) 54 (188 ) 6 Life sciences and engineering (25 ) (36 ) (74 ) (108 ) Earnings (Loss) from operations before income taxes (336 ) 8 (383 ) (513 ) Gain (Loss) on sale of businesses 2,136 (3 ) 2,136 (9 ) Income tax expense 433 0 433 0 Earnings (Loss) from discontinued operations $ 1,367 $ 5 $ 1,320 $ (522 ) Parkside Nursing Home — On March 17, 2019, a subsidiary of the Company sold its Parkside Ellijay Nursing Home (“Parkside”) and related real estate for $7,300 subject to adjustment for the book value of certain assets and liabilities on the sale date. The pre-tax gain on the sale is $2,136, which is also subject to adjustment for the book value of certain assets and liabilities on the sale date. The net proceeds of the sale were retained for working capital and general corporate purposes. Sold Hospitals – The loss before income taxes of the Sold Hospitals results primarily from retained professional liability claims expenses. Life Sciences and Engineering Segment —SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and nine months ended March 31, 2019 and 2018, respectively. The components of pension expense for the three and nine months ended March 31, 2019 and 2018, respectively, were as follows: Three Months Ended Nine Months Ended March 31, March 31, 2019 2018 2019 2018 Interest Cost $ 14 $ 14 $ 42 $ 42 Expected return on assets (9 ) (9 ) (27 ) (27 ) Amortization of prior service cost 20 31 59 93 Net pension expense $ 25 $ 36 $ 74 $ 108 SunLink contributed $80 to the plan in the nine months ended March 31, 2019 and expects to contribute an additional $28 during the last fiscal quarter of the fiscal year ending June 30, 2019. |
Shareholders' Equity
Shareholders' Equity | 9 Months Ended |
Mar. 31, 2019 | |
Federal Home Loan Banks [Abstract] | |
Shareholders' Equity | Note 4. – Shareholders’ Equity Common Share Repurchase Program – On November 29, 2018, the Company announced a share repurchase program (“Program”) approved by its Board of Directors, which authorized the Company to purchase up to 300,000 shares of its common shares. On December 13, 2018, the Company announced it had purchased the 300,000 shares authorized under the program, and that its Board of Directors had authorized an additional 450,000 shares to be purchased under the Program. As of March 31, 2019, a total of 359,959 shares had been repurchased at a cost of $372, excluding fees and expensing relating to the offer. Additional shares of 390,041 remain authorized to be repurchased. The chart below shows by month the total share repurchased and average price per share paid for the Program as of March 31, 2019. Total Shares Average Price Purchased Per Share Paid November 2018 1,235 $ 1.14 December 2018 358,724 1.03 Total 359,959 $ 1.03 Stock-Based Compensation – For the three months ended March 31, 2019 and 2018, the Company recognized $0 and $1, respectively, in stock based compensation for options issued to employees and directors of the Company. For the nine months ended March 31, 2019 and 2018, the Company recognized $1 and $7, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option-pricing model. There were no share options granted under the 2011 Director Stock Option Plan during the three and nine months ended March 31, 2019 and 2018, respectively, and the Company has 50,000 shares available for grants under the 2011 Director Stock Option Plan |
Revenue Recognition and Account
Revenue Recognition and Accounts Receivables | 9 Months Ended |
Mar. 31, 2019 | |
Receivables [Abstract] | |
Revenue Recognition and Accounts Receivables | Note 5. – Revenue Recognition and Accounts Receivables Revenue Recognition Effective July 1, 2018, the Company adopted the provisions of Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” which supersedes most existing revenue recognition guidance, including industry-specific healthcare guidance, by applying the full retrospective method for all periods presented. ASC 606 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The adoption of the provisions of ASC 606 had no material impact on the Company’s current or historical financial position, results of operations or cash flows. Additionally, management does not anticipate that the provisions of ASC 606 will have a material impact on the amount or timing of when the Company recognizes revenue prospectively. However, in accordance with ASC 606 the Company now recognizes the majority of its previously reported provision for doubtful accounts, primarily related to its self-pay patient population, as a direct reduction to revenues as an implicit pricing concession, instead of separately as a discrete deduction to arrive at revenue, and the related presentation of the allowance for doubtful accounts has been eliminated for all periods presented. Disaggregation of Revenue The Company disaggregates revenue from contracts with its patients by reportable operating segments and payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue is disclosed in Note 13, Financial Information by Segment. The Company’s service specific revenue recognition policies are as follows: Healthcare Services The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed. Pharmacy The Company’s revenue is derived primarily from providing pharmacy services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. Revenue is recognized when control of the promised goods or services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. Significant portions of the revenue from sales of pharmaceutical and medical products are reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as other third-party insurance payors, and reduces revenue at the revenue recognition date, to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total net revenues and receivables reported in the Company’s financial statements are recorded at the amount expected to be ultimately received from these payors. Medicare Revenue Net healthcare services revenue is recorded under the Medicare prospective payment system based on an episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if patient care was unusually costly; (b) a low utilization payment adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required; (e) the number of episodes of care provided to a patient, regardless of whether the same provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments. The Company makes adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Revenue is also adjusted for estimates for variable consideration. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. In addition to revenue recognized on completed services, the Company also recognizes a portion of revenue associated with services in progress. Services in progress are days of care that begin during the reporting period but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of services in progress at the end of the reporting period, expected Medicare revenue per episode and its estimate of the average percentage complete based on services performed. Non-Medicare Revenue The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for service-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. Revenue is recorded on an accrual basis based upon the date of service at amounts equal to its established or estimated per-visit rates, and adjusted for estimates for variable consideration, as applicable. Impact of New Revenue Guidance on Financial Statement Line Items The following tables summarize the impacts of adopting ASC 606 on the Company’s condensed consolidated statements of operations and comprehensive earnings (loss). There was no impact to the condensed consolidated balance sheet as of June 30, 2018 or condensed consolidated statements of cash flows for the year ended June 30, 2018 and for the year ended June 30, 2017, respectively. The majority of which was previously presented as bad debt expense of the Pharmacy Segment under operating expenses has been incorporated as an implicit price concession factored into the calculation of net revenues. Subsequent material events that alter the payor’s ability to pay are recorded as bad debt expense. There is no material change, related to the adoption of ASC 606, for the presentation of the Company’s Fiscal 2018 revenues or prior years. Historically, the Company only presented total revenue for all revenue services in “Operating Revenues”. What was previously presented as provision for bad debts of Pharmacy segment under operating expenses has been incorporated as an implicit price concession factored into the calculation of net revenues, as shown in the “Adjustments” line in the table below. The Condensed Consolidated Statement of Operations and Comprehensive Earnings (Loss) for the three and nine months ended March 31, 2017 have been restated to reflect the adoption of ASC 606. Subsequent material events that alter the payor’s ability to pay are recorded as bad debt expense. Prior period results reflect reclassifications, for comparative purposes, related to the adoption of ASC 606, for the presentation of the Company’s revenues. Historically, the Company only presented total revenue for all revenue services. This reclassification had no effect on the reported results of operations. Revenues for the nine months ended March 31, 2018 and the fiscal year ended June 30, 2018 are summarized in the following tables: Nine Months Ended Fiscal Years Ended June 30, March 31, 2018 2018 Total Net Revenues $ 35,435 $ 45,912 Adjustment for bad debts of Pharmacy segment (445 ) (703 ) Net Revenues $ 34,990 $ 45,209 Total Cost of goods sold $ 14,623 $ 18,529 Adjustment for bad debts of Pharmacy segment 0 0 Cost of goods sold $ 14,623 $ 18,529 Total Expenses $ 35,933 $ 45,492 Adjustment for bad debts of Pharmacy segment (445 ) (703 ) Total Expenses $ 35,488 $ 44,789 Practical Expedients and Exemptions The Company’s contracts with its patients have an original duration of one year or less, therefore, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less. Revenues by payor were as follows for the three and nine months ended March 31, 2019 and 2018: Three Months Ended Nine Months Ended March 31, March 31, 2019 2018 2019 2018 Medicare $ 5,934 $ 4,337 13,517 14,139 Medicaid 2,743 3,539 10,890 9,744 Retail and Institutional Pharmacy 1,698 1,609 4,973 5,052 Managed Care & Other Insurance 1,871 1,707 4,743 5,394 Self-pay 65 104 449 526 Rent 22 21 52 48 Other 28 16 95 87 Total Net Revenues $ 12,361 $ 11,333 $ 34,719 $ 34,990 Summary information for accounts receivable is as follows: March 31, 2019 June 30, 2018 Accounts receivable (net of contractual allowances) $ 5,717 $ 5,352 Less allowance for concession adjustments (466 ) (529 ) Patient accounts receivable - net $ 5,251 $ 4,823 The following is a summary of the activity in the allowance for concession adjustments for the Healthcare Services Segment and the Pharmacy Segment for the three and nine months ended March 31, 2019 and 2018: Three Months Ended March 31, 2019 Healthcare Services Pharmacy Total Balance at January 1, 2019 $ 231 $ 228 $ 459 Additions recognized as a reduction to revenues: Continuing Operations 106 140 246 Discontinued Operations 15 0 15 Accounts written off, net of recoveries (87 ) (167 ) (254 ) Balance at March 31, 2019 $ 265 $ 201 $ 466 Nine Months Ended March 31, 2019 Healthcare Services Pharmacy Total Balance at July 1, 2018 $ 253 $ 276 $ 529 Additions recognized as a reduction to revenues: Continuing Operations 236 339 575 Discontinued Operations 23 0 23 Accounts written off, net of recoveries (247 ) (414 ) (661 ) Balance at March 31, 2019 $ 265 $ 201 $ 466 Three Months Ended March 31, 2018 Healthcare Services Pharmacy Total Balance at January 1, 2018 $ 326 $ 219 $ 545 Additions recognized as a reduction to revenues: Continuing Operations 117 237 354 Discontinued Operations 12 0 12 Accounts written off, net of recoveries (82 ) (260 ) (342 ) Balance at March 31, 2018 $ 373 $ 196 $ 569 Nine months Ended March 31, 2018 Healthcare Services Pharmacy Total Balance at July 1, 2017 $ 328 $ 224 $ 552 Additions recognized as a reduction to revenues: Continuing Operations 371 445 816 Discontinued Operations (6 ) 0 (6 ) Accounts written off, net of recoveries (320 ) (473 ) (793 ) Balance at March 31, 2018 $ 373 $ 196 $ 569 |
Intangible Assets
Intangible Assets | 9 Months Ended |
Mar. 31, 2019 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Note 6. – Intangible Assets Intangibles consist of the following, net of amortization: March 31, 2019 June 30, 2018 Pharmacy Segment Intangibles Trade Name (non-amortizing) $ 1,180 $ 1,180 Customer Relationships 1,089 1,089 Medicare License 623 623 2,892 2,892 Accumulated Amortization (1,509 ) (1,422 ) Net Intangibles $ 1,383 $ 1,470 Amortization expense was $29 and $29 for the three months ended March 31, 2019 and 2018, respectively. Amortization expense was $87 and $87 for the nine months ended March 31, 2019 and 2018, respectively. |
Long-Term Debt
Long-Term Debt | 9 Months Ended |
Mar. 31, 2019 | |
Debt Disclosure [Abstract] | |
Long-Term Debt | Note 7. –Long-Term Debt Long-term debt consisted of the following: March 31, 2019 June 30, 2018 Trace RDA Loan $ 3,093 $ 3,277 Capital Lease 166 0 Less unamortized debt issuance costs (201 ) (219 ) Less current maturities (319 ) (255 ) Long-term Debt $ 2,739 $ 2,803 Trace RDA Loan— Southern Health Corporation of Houston, Inc. (“Trace”) a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) with a bank, dated as of July 5, 2012. The Trace RDA Loan has a term of 15 years with level monthly payments of principal and interest until repaid. On December 26, 2017, the Fifth Amendment to Loan Agreement, Modification of Note and Waiver (“Modification”) was entered into by Trace and the bank. Under the Modification, Trace made a $3,548 prepayment on the Trace RDA Loan. The monthly principal and interest payments on the RDA Loan were reduced, the interest rate was reduced to the prime rate (as published in the Wall Street Journal) plus 1% with a floor of 5.5% , (6.5% at March 31, 2019) and certain loan covenants were modified. Management was not aware of any violations with the amended financial covenants at March 31, 2019. The Trace RDA Loan is collateralized by real estate and equipment of Trace in Houston, MS, and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis that require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash, including from operating activities and asset sales. If Trace is unable to generate sufficient cash to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary. |
Income Taxes
Income Taxes | 9 Months Ended |
Mar. 31, 2019 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 8. – Income Taxes Income tax benefit of $226 ($189 federal benefit and $37 state tax benefit) and income tax expense of $0 ($0 federal tax expense and state tax expense) was recorded for continuing operations for the three months ended March 31, 2019 and 2018, respectively. Income tax benefit of $226 ($189 federal benefit and $37 state tax benefit) and income tax benefit of $296 ($296 federal tax benefit and $0 state tax expense) was recorded for continuing operations for the nine months ended March 31, 2019 and 2018, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017. Under ASC 740, the impact of changes in tax law must be recorded in the financial statements in the reporting period that included the date of enactment. In addition, in conjunction with the TCJA, on December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), which provides guidance on accounting for the tax effects of the TCJA. SAB 118 allows for recording certain effects of the TCJA as “provisional” during a one-year measurement period, which for the Company ended in the second quarter of fiscal 2019. At March 31, 2019, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $8,113 against the deferred tax asset so that there is no net long-term deferred income tax asset or liability at March 31, 2019. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. The principal negative evidence that led us to determine at March 31, 2019 that all the deferred tax assets should have full valuation allowances was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate. For Federal income tax purposes, at March 31, 2019, the Company had approximately $14,900 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire primarily in fiscal 2023 through fiscal 2038; however, with the enactment of the TCJA on December 22, 2017, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 now have no expiration date. We recorded a discrete net tax benefit of $0 during the twelve months ended June 30, 2018 related to provisional amounts under SAB 118 for the remeasurement of U.S. deferred tax assets and liabilities due to the Federal tax rate reduction to 21%. No net tax benefit was recorded due to the Company’s full valuation allowance position. The $296 of tax benefit recorded for the nine months ended March 31, 2018 was due to the release of the valuation allowance on the Company’s Alternative Minimum Tax (“AMT”) Credit, which became refundable under the TCJA. No |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Mar. 31, 2019 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 9. – Commitments and Contingencies Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2019 were as follows: Payments due in: Long-Term Debt Operating Leases Interest on Outstanding Debt 1 year $ 319 $ 491 $ 206 2 years 341 295 184 3 years 365 87 161 4 years 389 7 136 5+ years 1,845 0 278 $ 3,259 $ 880 $ 965 Contingencies do not reflect potential amounts for claims, litigation and other uncertainties, which matters are not probable or cannot be estimated, such as for certain professional liabilities and contract matters relating to prior assets sales. |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Mar. 31, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Note 10. – Related Party Transactions A director of the Company is a member of a law firm which provides services to SunLink. The Company expensed an aggregate of $117 and $25 for legal services to this law firm in the three months ended March 31, 2019 and 2018, respectively. The Company expensed an aggregate of $252 and $215 for legal services to this law firm in the nine months ended March 31, 2019 and 2018, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2019 and June 30, 2018 is $48 and $10, respectively, of amounts payable to this law firm. |
Asset Sale
Asset Sale | 9 Months Ended |
Mar. 31, 2019 | |
Asset Sale [Abstract] | |
Asset Sale | Note 11. – Asset Sale On October 11, 2018, the Company sold a vacant medical office building and approximately two adjacent acres of undeveloped land. After expenses, the Company received net proceeds from the sale of $935, which was retained for working capital and general corporate purposes. The pre-tax gain on the sale of property was $452 and is included in the Company’s nine months ended March 31, 2019. |
Economic Damages Claim
Economic Damages Claim | 9 Months Ended |
Mar. 31, 2019 | |
Commitments And Contingencies Disclosure [Abstract] | |
Economic Damages Claim | Note 12. – Economic Damages Claim The Pharmacy Segment subsidiary asserted claims for economic damages in connection with the Deepwater Horizon Settlement Program related to the event which occurred in 2010. In January 2018, these claims were settled and payments of approximately $944 (net of costs and attorneys’ fees) were received. The net settlements are recognized as a gain in the Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) for the nine months ended March 31, 2018 |
Financial Information by Segmen
Financial Information by Segment | 9 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
Financial Information by Segment | Note 13. – Financial Information by Segment Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Services and Pharmacy. We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of March 31, 2019 and 2018 and for the three and nine months then ended is as follows: Healthcare Services Pharmacy Corporate and Other Total As of and for the three months ended March 31, 2019, Net revenues from external customers $ 3,966 $ 8,395 $ 0 $ 12,361 Operating profit (loss) (61 ) 65 (492 ) (488 ) Depreciation and amortization 82 284 1 367 Assets 8,758 8,519 9,783 27,060 Expenditures for property, plant and equipment (23 ) 246 0 223 As of and for the three months ended March 31, 2018, Net revenues from external customers $ 3,810 $ 7,523 $ 0 $ 11,333 Operating profit (loss) $ 124 $ (367 ) $ (477 ) (720 ) Depreciation and amortization 86 297 0 383 Assets 14,394 9,104 4,293 27,791 Expenditures for property, plant and equipment 15 263 0 278 As of and for the nine months ended March 31, 2019, Net revenues from external customers $ 11,738 $ 22,981 $ 0 $ 34,719 Operating profit (loss) 48 69 (1,465 ) (1,348 ) Depreciation and amortization 248 806 2 1,056 Assets 8,758 8,519 9,783 27,060 Expenditures for property, plant and equipment 179 688 0 867 As of and for the nine months ended March 31, 2018, Net revenues from external customers $ 11,810 $ 23,180 $ 0 $ 34,990 Operating profit (loss) 530 285 (1,313 ) (498 ) Depreciation and amortization 249 845 2 1,096 Assets 14,394 9,104 4,293 27,791 Expenditures for property, plant and equipment 291 522 0 813 |
Basis of Presentation and Ado_2
Basis of Presentation and Adoption of Recently Issued Accounting Standards (Policies) | 9 Months Ended |
Mar. 31, 2019 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2019 and for the three and nine month periods ended March 31, 2019 and 2018 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2018 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2018, filed with the SEC on September 25, 2018. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2019 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. |
Adoption of Recently Issued Accounting Standards | Adoption of Recently Issued Accounting Standards ASC 606, “Revenue from Contracts with Customers” Effective July 1, 2018, the Company adopted the provisions of Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” (“ASC 606”), which supersedes most existing revenue recognition guidance, including industry-specific healthcare guidance, by applying the full retrospective method for all periods presented. ASC 606 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The adoption of the provisions of ASC 606 had no material impact on the Company’s current or historical financial position, results of operations or cash flows. Additionally, management does not anticipate that the provisions of ASC 606 will have a material impact on the amount or timing of when the Company recognizes revenue prospectively. However, in accordance with ASC 606, the Company now recognizes the majority of its previously reported provision for doubtful accounts, primarily related to its self-pay patient population, as a direct reduction to revenues as an implicit pricing concession, instead of separately as a discrete deduction to arrive at revenue, and the related presentation of the allowance for doubtful accounts has been eliminated for all periods presented. The Company’s revenue recognition and accounts receivable policies are more fully described in Note 5. |
Discontinued Operations (Tables
Discontinued Operations (Tables) | 9 Months Ended |
Mar. 31, 2019 | |
Discontinued Operations And Disposal Groups [Abstract] | |
Schedule of Discontinued Operations | Results for all of the businesses included in discontinued operations are presented in the following table: Three Months Ended Nine Months Ended March 31, March 31, 2019 2018 2019 2018 Net Revenues: Parkside $ 1,723 $ 1,846 $ 5,640 $ 5,223 Sold Hospitals 3 77 15 71 $ 1,726 $ 1,923 $ 5,655 $ 5,294 Loss before income taxes: Parkside $ (185 ) $ (10 ) $ (121 ) $ (411 ) Sold Hospitals (126 ) 54 (188 ) 6 Life sciences and engineering (25 ) (36 ) (74 ) (108 ) Earnings (Loss) from operations before income taxes (336 ) 8 (383 ) (513 ) Gain (Loss) on sale of businesses 2,136 (3 ) 2,136 (9 ) Income tax expense 433 0 433 0 Earnings (Loss) from discontinued operations $ 1,367 $ 5 $ 1,320 $ (522 ) |
Components of Pension Expense | The components of pension expense for the three and nine months ended March 31, 2019 and 2018, respectively, were as follows: Three Months Ended Nine Months Ended March 31, March 31, 2019 2018 2019 2018 Interest Cost $ 14 $ 14 $ 42 $ 42 Expected return on assets (9 ) (9 ) (27 ) (27 ) Amortization of prior service cost 20 31 59 93 Net pension expense $ 25 $ 36 $ 74 $ 108 |
Shareholders' Equity (Tables)
Shareholders' Equity (Tables) | 9 Months Ended |
Mar. 31, 2019 | |
Federal Home Loan Banks [Abstract] | |
Summary of Total Share Repurchased and Average Price Per Share Paid for the Program | The chart below shows by month the total share repurchased and average price per share paid for the Program as of March 31, 2019. Total Shares Average Price Purchased Per Share Paid November 2018 1,235 $ 1.14 December 2018 358,724 1.03 Total 359,959 $ 1.03 |
Revenue Recognition and Accou_2
Revenue Recognition and Accounts Receivables (Tables) | 9 Months Ended |
Mar. 31, 2019 | |
Summary of Revenues by Payor | Revenues by payor were as follows for the three and nine months ended March 31, 2019 and 2018: Three Months Ended Nine Months Ended March 31, March 31, 2019 2018 2019 2018 Medicare $ 5,934 $ 4,337 13,517 14,139 Medicaid 2,743 3,539 10,890 9,744 Retail and Institutional Pharmacy 1,698 1,609 4,973 5,052 Managed Care & Other Insurance 1,871 1,707 4,743 5,394 Self-pay 65 104 449 526 Rent 22 21 52 48 Other 28 16 95 87 Total Net Revenues $ 12,361 $ 11,333 $ 34,719 $ 34,990 |
Summary Information for Accounts Receivable | Summary information for accounts receivable is as follows: March 31, 2019 June 30, 2018 Accounts receivable (net of contractual allowances) $ 5,717 $ 5,352 Less allowance for concession adjustments (466 ) (529 ) Patient accounts receivable - net $ 5,251 $ 4,823 |
Summary of Allowance for Concession Adjustments | The following is a summary of the activity in the allowance for concession adjustments for the Healthcare Services Segment and the Pharmacy Segment for the three and nine months ended March 31, 2019 and 2018: Three Months Ended March 31, 2019 Healthcare Services Pharmacy Total Balance at January 1, 2019 $ 231 $ 228 $ 459 Additions recognized as a reduction to revenues: Continuing Operations 106 140 246 Discontinued Operations 15 0 15 Accounts written off, net of recoveries (87 ) (167 ) (254 ) Balance at March 31, 2019 $ 265 $ 201 $ 466 Nine Months Ended March 31, 2019 Healthcare Services Pharmacy Total Balance at July 1, 2018 $ 253 $ 276 $ 529 Additions recognized as a reduction to revenues: Continuing Operations 236 339 575 Discontinued Operations 23 0 23 Accounts written off, net of recoveries (247 ) (414 ) (661 ) Balance at March 31, 2019 $ 265 $ 201 $ 466 Three Months Ended March 31, 2018 Healthcare Services Pharmacy Total Balance at January 1, 2018 $ 326 $ 219 $ 545 Additions recognized as a reduction to revenues: Continuing Operations 117 237 354 Discontinued Operations 12 0 12 Accounts written off, net of recoveries (82 ) (260 ) (342 ) Balance at March 31, 2018 $ 373 $ 196 $ 569 Nine months Ended March 31, 2018 Healthcare Services Pharmacy Total Balance at July 1, 2017 $ 328 $ 224 $ 552 Additions recognized as a reduction to revenues: Continuing Operations 371 445 816 Discontinued Operations (6 ) 0 (6 ) Accounts written off, net of recoveries (320 ) (473 ) (793 ) Balance at March 31, 2018 $ 373 $ 196 $ 569 |
Accounting Standards Update 2014-09 [Member] | |
Summary of Revenues | Revenues for the nine months ended March 31, 2018 and the fiscal year ended June 30, 2018 are summarized in the following tables: Nine Months Ended Fiscal Years Ended June 30, March 31, 2018 2018 Total Net Revenues $ 35,435 $ 45,912 Adjustment for bad debts of Pharmacy segment (445 ) (703 ) Net Revenues $ 34,990 $ 45,209 Total Cost of goods sold $ 14,623 $ 18,529 Adjustment for bad debts of Pharmacy segment 0 0 Cost of goods sold $ 14,623 $ 18,529 Total Expenses $ 35,933 $ 45,492 Adjustment for bad debts of Pharmacy segment (445 ) (703 ) Total Expenses $ 35,488 $ 44,789 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 9 Months Ended |
Mar. 31, 2019 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Intangibles consist of the following, net of amortization: March 31, 2019 June 30, 2018 Pharmacy Segment Intangibles Trade Name (non-amortizing) $ 1,180 $ 1,180 Customer Relationships 1,089 1,089 Medicare License 623 623 2,892 2,892 Accumulated Amortization (1,509 ) (1,422 ) Net Intangibles $ 1,383 $ 1,470 |
Long-Term Debt (Tables)
Long-Term Debt (Tables) | 9 Months Ended |
Mar. 31, 2019 | |
Debt Disclosure [Abstract] | |
Summary of Long-Term Debt | Long-term debt consisted of the following: March 31, 2019 June 30, 2018 Trace RDA Loan $ 3,093 $ 3,277 Capital Lease 166 0 Less unamortized debt issuance costs (201 ) (219 ) Less current maturities (319 ) (255 ) Long-term Debt $ 2,739 $ 2,803 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 9 Months Ended |
Mar. 31, 2019 | |
Commitments And Contingencies Disclosure [Abstract] | |
Schedule of Contractual Obligations, Commitments and Contingencies | Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2019 were as follows: Payments due in: Long-Term Debt Operating Leases Interest on Outstanding Debt 1 year $ 319 $ 491 $ 206 2 years 341 295 184 3 years 365 87 161 4 years 389 7 136 5+ years 1,845 0 278 $ 3,259 $ 880 $ 965 |
Financial Information by Segm_2
Financial Information by Segment (Tables) | 9 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
Segment Information | Segment information as of March 31, 2019 and 2018 and for the three and nine months then ended is as follows: Healthcare Services Pharmacy Corporate and Other Total As of and for the three months ended March 31, 2019, Net revenues from external customers $ 3,966 $ 8,395 $ 0 $ 12,361 Operating profit (loss) (61 ) 65 (492 ) (488 ) Depreciation and amortization 82 284 1 367 Assets 8,758 8,519 9,783 27,060 Expenditures for property, plant and equipment (23 ) 246 0 223 As of and for the three months ended March 31, 2018, Net revenues from external customers $ 3,810 $ 7,523 $ 0 $ 11,333 Operating profit (loss) $ 124 $ (367 ) $ (477 ) (720 ) Depreciation and amortization 86 297 0 383 Assets 14,394 9,104 4,293 27,791 Expenditures for property, plant and equipment 15 263 0 278 As of and for the nine months ended March 31, 2019, Net revenues from external customers $ 11,738 $ 22,981 $ 0 $ 34,719 Operating profit (loss) 48 69 (1,465 ) (1,348 ) Depreciation and amortization 248 806 2 1,056 Assets 8,758 8,519 9,783 27,060 Expenditures for property, plant and equipment 179 688 0 867 As of and for the nine months ended March 31, 2018, Net revenues from external customers $ 11,810 $ 23,180 $ 0 $ 34,990 Operating profit (loss) 530 285 (1,313 ) (498 ) Depreciation and amortization 249 845 2 1,096 Assets 14,394 9,104 4,293 27,791 Expenditures for property, plant and equipment 291 522 0 813 |
Business Operations - Additiona
Business Operations - Additional Information (Detail) $ in Thousands | May 17, 2019USD ($) | Dec. 13, 2018shares | Mar. 31, 2019USD ($) | Mar. 31, 2018USD ($) | Mar. 31, 2019USD ($)SegmentBedServiceshares | Mar. 31, 2018USD ($) | Nov. 29, 2018shares |
Business And Organization [Line Items] | |||||||
Number of segments | Segment | 2 | ||||||
Proceeds from sale | $ 6,899 | $ 0 | |||||
Pre-tax gain on the sale | $ 2,136 | $ (3) | $ 2,136 | $ (9) | |||
Number of shares authorized to be repurchased | shares | 750,000 | ||||||
Stock repurchased during period, shares | shares | 300,000 | 359,959 | |||||
Parkside [Member] | |||||||
Business And Organization [Line Items] | |||||||
Proceeds from sale | $ 7,300 | ||||||
Pre-tax gain on the sale | $ 2,136 | ||||||
Healthcare Services Segment [Member] | Community Hospital [Member] | |||||||
Business And Organization [Line Items] | |||||||
Number of licensed-bed owned and operated by a subsidiary | Bed | 84 | ||||||
Healthcare Services Segment [Member] | Nursing Home [Member] | Mississippi [Member] | |||||||
Business And Organization [Line Items] | |||||||
Number of bed in nursing home owned and operated by subsidiary | Bed | 66 | ||||||
Pharmacy Segment [Member] | Louisiana [Member] | |||||||
Business And Organization [Line Items] | |||||||
Number of material service lines | Service | 4 |
Discontinued Operations - Sched
Discontinued Operations - Schedule of Discontinued Operations (Detail) - USD ($) $ in Thousands | May 17, 2019 | Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 |
Net Revenues: | |||||
Net revenues | $ 1,726 | $ 1,923 | $ 5,655 | $ 5,294 | |
Loss before income taxes: | |||||
Loss before income taxes | (336) | 8 | (383) | (513) | |
Gain (Loss) on sale of businesses | 2,136 | (3) | 2,136 | (9) | |
Income tax expense | 433 | 0 | 433 | 0 | |
Earnings (Loss) from discontinued operations | 1,367 | 5 | 1,320 | (522) | |
Parkside [Member] | |||||
Net Revenues: | |||||
Net revenues | 1,723 | 1,846 | 5,640 | 5,223 | |
Loss before income taxes: | |||||
Loss before income taxes | (185) | (10) | (121) | (411) | |
Gain (Loss) on sale of businesses | $ 2,136 | ||||
Sold Hospitals [Member] | |||||
Net Revenues: | |||||
Net revenues | 3 | 77 | 15 | 71 | |
Loss before income taxes: | |||||
Loss before income taxes | (126) | 54 | (188) | 6 | |
Life Sciences and Engineering [Member] | |||||
Loss before income taxes: | |||||
Loss before income taxes | $ (25) | $ (36) | $ (74) | $ (108) |
Discontinued Operations - Addit
Discontinued Operations - Additional Information (Detail) - USD ($) $ in Thousands | May 17, 2019 | Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Proceeds from sale | $ 6,899 | $ 0 | |||
Pre-tax gain on the sale | $ 2,136 | $ (3) | 2,136 | $ (9) | |
Parkside [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Proceeds from sale | $ 7,300 | ||||
Pre-tax gain on the sale | $ 2,136 | ||||
Life Sciences and Engineering [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Contribution to pension plan | 80 | ||||
Expected contribution to pension plan during the remaining fiscal year | $ 28 | $ 28 |
Discontinued Operations - Compo
Discontinued Operations - Components of Pension Expense (Detail) - Life Sciences and Engineering [Member] - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | |
Defined Benefit Plan Disclosure [Line Items] | ||||
Defined Benefit Plan, Type [Extensible List] | us-gaap:PensionPlansDefinedBenefitMember | us-gaap:PensionPlansDefinedBenefitMember | us-gaap:PensionPlansDefinedBenefitMember | us-gaap:PensionPlansDefinedBenefitMember |
Interest Cost | $ 14 | $ 14 | $ 42 | $ 42 |
Expected return on assets | (9) | (9) | (27) | (27) |
Amortization of prior service cost | 20 | 31 | 59 | 93 |
Net pension expense | $ 25 | $ 36 | $ 74 | $ 108 |
Shareholders' Equity - Addition
Shareholders' Equity - Additional Information (Detail) - USD ($) $ in Thousands | Dec. 13, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Nov. 29, 2018 |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Number of shares authorized to be repurchased | 750,000 | |||||
Stock repurchased during period, shares | 300,000 | 359,959 | ||||
Additional shares authorized for purchase | 450,000 | 390,041 | 390,041 | |||
Stock repurchased during period, value | $ 372 | |||||
Share-based compensation, amount recognized | $ 0 | $ 1 | $ 1 | $ 7 | ||
2011 Director Stock Option Plan [Member] | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Options granted | 0 | 0 | 0 | 0 | ||
Shares available for grants | 50,000 | 50,000 | ||||
Maximum [Member] | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Number of shares authorized to be repurchased | 300,000 |
Shareholders' Equity - Summary
Shareholders' Equity - Summary of Total Share Repurchased and Average Price Per Share Paid for the Program (Detail) - $ / shares | Dec. 13, 2018 | Mar. 31, 2019 |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Total Shares Purchased | 300,000 | 359,959 |
Average Price Per Share Paid | $ 1.03 | |
November 2018 | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Total Shares Purchased | 1,235 | |
Average Price Per Share Paid | $ 1.14 | |
December 2018 | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Total Shares Purchased | 358,724 | |
Average Price Per Share Paid | $ 1.03 |
Revenue Recognition and Accou_3
Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Jun. 30, 2018 | |
Segment Reporting Revenue Reconciling Item [Line Items] | |||||
Revenues | $ 12,361 | $ 11,333 | $ 34,719 | $ 34,990 | $ 45,209 |
Cost of goods sold | 14,623 | 18,529 | |||
Total Expenses | 35,488 | 44,789 | |||
Accounting Standards Update 2014-09 [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member] | |||||
Segment Reporting Revenue Reconciling Item [Line Items] | |||||
Revenues | 35,435 | 45,912 | |||
Cost of goods sold | 14,623 | 18,529 | |||
Total Expenses | 35,933 | 45,492 | |||
Accounting Standards Update 2014-09 [Member] | Adjustment for Bad Debts of Pharmacy Segment [Member] | |||||
Segment Reporting Revenue Reconciling Item [Line Items] | |||||
Revenues | (445) | (703) | |||
Cost of goods sold | 0 | 0 | |||
Total Expenses | $ (445) | $ (703) |
Revenue Recognition and Accou_4
Revenue Recognition and Accounts Receivables - Summary of Revenue by Payor (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Jun. 30, 2018 | |
Segment Reporting Revenue Reconciling Item [Line Items] | |||||
Net revenues | $ 12,361 | $ 11,333 | $ 34,719 | $ 34,990 | $ 45,209 |
Medicare [Member] | |||||
Segment Reporting Revenue Reconciling Item [Line Items] | |||||
Net revenues | 5,934 | 4,337 | 13,517 | 14,139 | |
Medicaid [Member] | |||||
Segment Reporting Revenue Reconciling Item [Line Items] | |||||
Net revenues | 2,743 | 3,539 | 10,890 | 9,744 | |
Retail and Institutional Pharmacy [Member] | |||||
Segment Reporting Revenue Reconciling Item [Line Items] | |||||
Net revenues | 1,698 | 1,609 | 4,973 | 5,052 | |
Managed Care & Other Insurance [Member] | |||||
Segment Reporting Revenue Reconciling Item [Line Items] | |||||
Net revenues | 1,871 | 1,707 | 4,743 | 5,394 | |
Self-Pay [Member] | |||||
Segment Reporting Revenue Reconciling Item [Line Items] | |||||
Net revenues | 65 | 104 | 449 | 526 | |
Rent [Member] | |||||
Segment Reporting Revenue Reconciling Item [Line Items] | |||||
Net revenues | 22 | 21 | 52 | 48 | |
Other [Member] | |||||
Segment Reporting Revenue Reconciling Item [Line Items] | |||||
Net revenues | $ 28 | $ 16 | $ 95 | $ 87 |
Revenue Recognition and Accou_5
Revenue Recognition and Accounts Receivables - Summary Information for Receivable (Detail) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 | Jun. 30, 2017 |
Receivables [Abstract] | ||||||
Accounts receivable (net of contractual allowances) | $ 5,717 | $ 5,352 | ||||
Less allowance for concession adjustments | (466) | $ (459) | (529) | $ (569) | $ (545) | $ (552) |
Patient accounts receivable - net | $ 5,251 | $ 4,823 |
Revenue Recognition and Accou_6
Revenue Recognition and Accounts Receivables - Summary of Allowance for Concession Adjustments (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | |
Segment Reporting Revenue Reconciling Item [Line Items] | ||||
Beginning balance | $ 459 | $ 545 | $ 529 | $ 552 |
Accounts written off, net of recoveries | (254) | (342) | (661) | (793) |
Ending balance | 466 | 569 | 466 | 569 |
Continuing Operations [Member] | ||||
Segment Reporting Revenue Reconciling Item [Line Items] | ||||
Additions recognized as a reduction to revenues | 246 | 354 | 575 | 816 |
Discontinued Operations [Member] | ||||
Segment Reporting Revenue Reconciling Item [Line Items] | ||||
Additions recognized as a reduction to revenues | 15 | 12 | 23 | (6) |
Healthcare Services Segment [Member] | ||||
Segment Reporting Revenue Reconciling Item [Line Items] | ||||
Beginning balance | 231 | 326 | 253 | 328 |
Accounts written off, net of recoveries | (87) | (82) | (247) | (320) |
Ending balance | 265 | 373 | 265 | 373 |
Healthcare Services Segment [Member] | Continuing Operations [Member] | ||||
Segment Reporting Revenue Reconciling Item [Line Items] | ||||
Additions recognized as a reduction to revenues | 106 | 117 | 236 | 371 |
Healthcare Services Segment [Member] | Discontinued Operations [Member] | ||||
Segment Reporting Revenue Reconciling Item [Line Items] | ||||
Additions recognized as a reduction to revenues | 15 | 12 | 23 | (6) |
Pharmacy Segment [Member] | ||||
Segment Reporting Revenue Reconciling Item [Line Items] | ||||
Beginning balance | 228 | 219 | 276 | 224 |
Accounts written off, net of recoveries | (167) | (260) | (414) | (473) |
Ending balance | 201 | 196 | 201 | 196 |
Pharmacy Segment [Member] | Continuing Operations [Member] | ||||
Segment Reporting Revenue Reconciling Item [Line Items] | ||||
Additions recognized as a reduction to revenues | 140 | 237 | 339 | 445 |
Pharmacy Segment [Member] | Discontinued Operations [Member] | ||||
Segment Reporting Revenue Reconciling Item [Line Items] | ||||
Additions recognized as a reduction to revenues | $ 0 | $ 0 | $ 0 | $ 0 |
Intangible Assets - Intangible
Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands | Mar. 31, 2019 | Jun. 30, 2018 |
Indefinite-lived Intangible Assets [Line Items] | ||
Total | $ 1,383 | $ 1,470 |
Specialty Pharmacy Segment [Member] | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Finite and Indefinite-Lived Intangible Assets, Gross | 2,892 | 2,892 |
Accumulated Amortization | (1,509) | (1,422) |
Total | 1,383 | 1,470 |
Trade Name [Member] | Specialty Pharmacy Segment [Member] | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Indefinite-Lived Intangible Assets | 1,180 | 1,180 |
Customer Relationships [Member] | Specialty Pharmacy Segment [Member] | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Assets, Gross | 1,089 | 1,089 |
Medicare License [Member] | Specialty Pharmacy Segment [Member] | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Assets, Gross | $ 623 | $ 623 |
Intangible Assets - Additional
Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | |
Goodwill And Intangible Assets Disclosure [Abstract] | ||||
Amortization expense | $ 29 | $ 29 | $ 87 | $ 87 |
Long-Term Debt - Summary of Lon
Long-Term Debt - Summary of Long-Term Debt (Detail) - USD ($) $ in Thousands | Mar. 31, 2019 | Jun. 30, 2018 |
Debt Instrument [Line Items] | ||
Capital Lease | $ 166 | $ 0 |
Less unamortized debt issuance costs | (201) | (219) |
Less current maturities | (319) | (255) |
Long-term Debt | 2,739 | 2,803 |
Trace RDA Loan [Member] | ||
Debt Instrument [Line Items] | ||
Trace RDA Loan | $ 3,093 | $ 3,277 |
Long-Term Debt (Trace RDA Loan
Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) - USD ($) $ in Thousands | Dec. 26, 2017 | Mar. 31, 2019 | Mar. 31, 2018 |
Debt Instrument [Line Items] | |||
Prepayment of loan | $ 193 | $ 3,856 | |
Trace RDA Loan [Member] | |||
Debt Instrument [Line Items] | |||
Debt instrument maturity period | 15 years | ||
Prepayment of loan | $ 3,548 | ||
Debt instrument description | Prime rate plus 1% with a floor of 5.5% | ||
Debt instrument interest rate, basis spread | 1.00% | ||
Debt instrument, interest rate floor | 5.50% | ||
Effective interest rate | 6.50% | ||
Trace RDA Loan [Member] | Mortgages [Member] | |||
Debt Instrument [Line Items] | |||
Loan agreement amount | $ 9,975 | ||
Date of loan agreement | Jul. 5, 2012 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Detail) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Jun. 30, 2018 | Mar. 31, 2017 | |
Income Tax Disclosure [Abstract] | ||||||
Income tax expense (benefit) | $ (226,000) | $ 0 | $ (226,000) | $ (296,000) | ||
Federal tax expense (benefit) | (189,000) | 0 | (189,000) | (296,000) | ||
State tax expense (benefit) | (37,000) | $ 0 | (37,000) | $ 0 | ||
Deferred income tax valuation allowance | 8,113,000 | 8,113,000 | ||||
Net long-term deferred income tax asset or liability | 0 | 0 | ||||
Net operating loss carry-forward | $ 14,900,000 | $ 14,900,000 | ||||
Net operating loss carryforward expiration year | 2023 through fiscal 2038 | |||||
Discrete net tax benefit | $ 0 | |||||
Federal tax rate percentage | 21.00% | |||||
Net tax benefit due to valuation allowance position | $ 0 | |||||
Provisional estimate | $ 0 | |||||
Federal alternative minimum tax, tax credits | 305,000 | $ 296,000 | ||||
Additional income tax expense benefit | $ 40,000 | |||||
Tax Cuts and Jobs Act, Accounting Complete | true |
Commitments and Contingencies -
Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) $ in Thousands | Mar. 31, 2019USD ($) |
Long-Term Debt [Member] | |
Commitment And Contingencies [Line Items] | |
Payments due in 1 year | $ 319 |
Payments due in 2 years | 341 |
Payments due in 3 years | 365 |
Payments due in 4 years | 389 |
Payments due in 5+ years | 1,845 |
Contractual obligations, commitments and contingencies | 3,259 |
Operating Leases [Member] | |
Commitment And Contingencies [Line Items] | |
Payments due in 1 year | 491 |
Payments due in 2 years | 295 |
Payments due in 3 years | 87 |
Payments due in 4 years | 7 |
Payments due in 5+ years | 0 |
Contractual obligations, commitments and contingencies | 880 |
Interest on Outstanding Debt [Member] | |
Commitment And Contingencies [Line Items] | |
Payments due in 1 year | 206 |
Payments due in 2 years | 184 |
Payments due in 3 years | 161 |
Payments due in 4 years | 136 |
Payments due in 5+ years | 278 |
Contractual obligations, commitments and contingencies | $ 965 |
Related Party Transactions - Ad
Related Party Transactions - Additional Information (Detail) - Management [Member] - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Jun. 30, 2018 | |
Related Party Transaction [Line Items] | |||||
Legal services to these law firms | $ 117 | $ 25 | $ 252 | $ 215 | |
Amount payable to law firms | $ 48 | $ 48 | $ 10 |
Asset Sale - Additional Informa
Asset Sale - Additional Information (Detail) $ in Thousands | Oct. 11, 2018USD ($)a | Mar. 31, 2019USD ($) | Mar. 31, 2018USD ($) | Mar. 31, 2019USD ($) | Mar. 31, 2018USD ($) |
Asset Sale [Line Items] | |||||
Proceeds from sale | $ 6,899 | $ 0 | |||
Pre-tax gain on the sale of property | $ 0 | $ 183 | 454 | $ 181 | |
Medical Office Building And Undeveloped Land [Member] | |||||
Asset Sale [Line Items] | |||||
Undeveloped land sold | a | 2 | ||||
Proceeds from sale | $ 935 | ||||
Pre-tax gain on the sale of property | $ 452 |
Economic Damages Claim - Additi
Economic Damages Claim - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2017 | |
Loss Contingencies [Line Items] | |||||
Gain on economic damages claim, net | $ 0 | $ 0 | $ 0 | $ 944 | |
Pharmacy Segment [Member] | |||||
Loss Contingencies [Line Items] | |||||
Gain on economic damages claim, net | $ 944 |
Financial Information by Segm_3
Financial Information by Segment - Additional Information (Detail) | 9 Months Ended |
Mar. 31, 2019Segment | |
Segment Reporting [Abstract] | |
Number of segments | 2 |
Financial Information by Segm_4
Financial Information by Segment - Segment Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Jun. 30, 2018 | |
Segment Reporting Information [Line Items] | |||||
Net revenues from external customers | $ 12,361 | $ 11,333 | $ 34,719 | $ 34,990 | $ 45,209 |
Operating profit (loss) | (488) | (720) | (1,348) | (498) | |
Depreciation and amortization | 367 | 383 | 1,056 | 1,096 | |
Assets | 27,060 | 27,791 | 27,060 | 27,791 | $ 26,176 |
Expenditures for property, plant and equipment | 223 | 278 | 867 | 813 | |
Operating Segments [Member] | Healthcare Services Segment [Member] | |||||
Segment Reporting Information [Line Items] | |||||
Net revenues from external customers | 3,966 | 3,810 | 11,738 | 11,810 | |
Operating profit (loss) | (61) | 124 | 48 | 530 | |
Depreciation and amortization | 82 | 86 | 248 | 249 | |
Assets | 8,758 | 14,394 | 8,758 | 14,394 | |
Expenditures for property, plant and equipment | (23) | 15 | 179 | 291 | |
Operating Segments [Member] | Pharmacy Segment [Member] | |||||
Segment Reporting Information [Line Items] | |||||
Net revenues from external customers | 8,395 | 7,523 | 22,981 | 23,180 | |
Operating profit (loss) | 65 | (367) | 69 | 285 | |
Depreciation and amortization | 284 | 297 | 806 | 845 | |
Assets | 8,519 | 9,104 | 8,519 | 9,104 | |
Expenditures for property, plant and equipment | 246 | 263 | 688 | 522 | |
Corporate and Other [Member] | |||||
Segment Reporting Information [Line Items] | |||||
Net revenues from external customers | 0 | 0 | 0 | 0 | |
Operating profit (loss) | (492) | (477) | (1,465) | (1,313) | |
Depreciation and amortization | 1 | 0 | 2 | 2 | |
Assets | 9,783 | 4,293 | 9,783 | 4,293 | |
Expenditures for property, plant and equipment | $ 0 | $ 0 | $ 0 | $ 0 |